199 related articles for article (PubMed ID: 38658964)
41. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
42. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
43. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
44. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
[TBL] [Abstract][Full Text] [Related]
45. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
Saddiki H; Fayosse A; Cognat E; Sabia S; Engelborghs S; Wallon D; Alexopoulos P; Blennow K; Zetterberg H; Parnetti L; Zerr I; Hermann P; Gabelle A; Boada M; Orellana A; de Rojas I; Lilamand M; Bjerke M; Van Broeckhoven C; Farotti L; Salvadori N; Diehl-Schmid J; Grimmer T; Hourregue C; Dugravot A; Nicolas G; Laplanche JL; Lehmann S; Bouaziz-Amar E; ; Hugon J; Tzourio C; Singh-Manoux A; Paquet C; Dumurgier J
PLoS Med; 2020 Aug; 17(8):e1003289. PubMed ID: 32817639
[TBL] [Abstract][Full Text] [Related]
46. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
[TBL] [Abstract][Full Text] [Related]
47. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
48. Imbalance of Circulating T
Oberstein TJ; Taha L; Spitzer P; Hellstern J; Herrmann M; Kornhuber J; Maler JM
Front Immunol; 2018; 9():1213. PubMed ID: 29915582
[TBL] [Abstract][Full Text] [Related]
49. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
[TBL] [Abstract][Full Text] [Related]
51. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
52. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
53. Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course.
Liguori C; Placidi F; Izzi F; Spanetta M; Mercuri NB; Di Pucchio A
Alzheimers Res Ther; 2020 Jan; 12(1):5. PubMed ID: 31901236
[TBL] [Abstract][Full Text] [Related]
54. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
55. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.
Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S
Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013
[TBL] [Abstract][Full Text] [Related]
56. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
[TBL] [Abstract][Full Text] [Related]
57. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
58. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
[TBL] [Abstract][Full Text] [Related]
60. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
